Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.
Jazz Pharmaceuticals plc licensed global development and commercialization rights to Werewolf Therapeutics, Inc.'s investigational WTX-613, a conditionally-activated interferon alpha (IFNα) Indukine molecule on 7 April
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?